Cationic Lipid Nanoparticles for Stable mRNA Vaccine Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current mRNA vaccines face challenges such as early degradation of the antigen and inefficient translation due to early mRNA degradation and inefficient release in cells, which limits their effectiveness and increases the dose required, posing safety concerns and making them less affordable for widespread use, especially in the third world.

Innovation Solution

The use of lipid nanoparticles (LNPs) encapsulating mRNA, comprising specific cationic lipids and optionally PEG lipids, to protect and deliver mRNA effectively, ensuring optimal drug:lipid ratios, protection from serum degradation, and efficient intracellular delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If mRNA vaccines are administered without lipid nanoparticle encapsulation, then the formulation is simpler and easier to manufacture, but the mRNA undergoes early degradation and inefficient release in cells, limiting effectiveness and requiring higher doses

Engineering Contradiction:

Improveease of manufactureVSAvoideffectiveness

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent employs lipid nanoparticles as a composite delivery system comprising multiple components: ionizable lipids (for endosomal escape), PEGylated lipids (for stability and reduced immunogenicity), cholesterol (for membrane fluidity), and helper lipids. This composite structure protects mRNA from degradation while facilitating efficient cellular uptake and release, thereby improving vaccine effectiveness without significantly complicating the manufacturing process

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The lipid nanoparticle acts as an intermediary carrier between the mRNA vaccine and the target cells. It mediates protection of mRNA from serum nucleases, facilitates cellular uptake through endocytosis, and enables endosomal escape to release intact mRNA into the cytoplasm for translation, thus bridging the gap between administration and functional expression

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If higher doses of mRNA vaccines are administered to overcome degradation and inefficiency, then the effectiveness may be improved, but safety concerns increase and affordability decreases

Engineering Contradiction:

ImproveeffectivenessVSAvoidsafety concerns

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent optimizes critical parameters of the lipid nanoparticle system including the pKa of ionizable lipids (5.5-7.5 for efficient endosomal escape), the ratio of lipid components (specifically 20-40% ionizable lipid, 10-30% PEGylated lipid, 30-50% cholesterol, and 10-30% helper lipid), and the size distribution (80-120 nm diameter). These parameter optimizations enable effective delivery at lower doses, reducing safety concerns and improving affordability

Inventive Principle:

Principle #35Parameter changes

3Reliability

If mRNA vaccines require frequent administration to maintain effectiveness, then the immune response may be sustained, but the complexity of treatment increases and accessibility decreases

Engineering Contradiction:

Improveimmune response sustainabilityVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The lipid nanoparticle formulation is designed to enable effective single-dose or limited-dose vaccination by pre-optimizing all critical parameters (lipid composition, particle size, mRNA loading efficiency). This preliminary optimization of the delivery system ensures that the mRNA is protected, efficiently delivered, and effectively translated from the first administration, reducing or eliminating the need for frequent boosters and simplifying the treatment regimen

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the stability and delivery of mRNA vaccines, allowing for a reduced dose to elicit an adaptive immune response, thereby improving safety and affordability, and making the vaccines more accessible for global use.

Implementation Method 1

a cationic lipid with the formula (I)... wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein

Methodology Applied

Scientific EffectElectrostatic interaction: Ion Repulsion/Attraction

Implementation Method 2

efficient intracellular delivery

Methodology Applied

Scientific EffectEndocytosis:

Implementation Method 3

efficient release in cells

Methodology Applied

Scientific EffectEndosomal escape:

Implementation Method 4

optionally PEG lipids... protection from serum degradation

Methodology Applied

Scientific EffectSteric stabilization:

Data Source

PatentUS20250288522A1LIPID NANOPARTICLE mRNA VACCINES

Publication Date: 2025.09.18 CUREVAC SE

AI summary

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.